Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density.
10.6118/jmm.2016.22.3.174
- Author:
Young Hwa CHO
1
;
Mi Jung UM
;
Suk Jin KIM
;
Soo Ah KIM
;
Hyuk JUNG
Author Information
1. Department of Obstetrics and Gynecology, Cheomdan Hospital, Gwangju, Korea.
- Publication Type:Original Article
- Keywords:
Bone mineral density;
Endometriosis;
Gonadotropin-releasing hormone agonist;
Raloxifene hydrochloride
- MeSH:
Bone Density*;
Endometriosis*;
Female;
Femur;
Femur Neck;
Gonadotropin-Releasing Hormone*;
Humans;
Leuprolide;
Raloxifene Hydrochloride*;
Spine
- From:Journal of Menopausal Medicine
2016;22(3):174-179
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: To evaluate the efficacy of raloxifene in preventing bone loss associated with long term gonadotropin-releasing hormone agonist (GnRH-a) administration. METHODS: Twenty-two premenopausal women with severe endometriosis were treated with leuprolide acetate depot at a dosage of 3.75 mg/4 weeks, for 48 weeks. Bone mineral density (BMD) was evaluated at admission, and after 12 treatment cycles. RESULTS: At cycle 12 of GnRH-a plus raloxifene treatment, lumbar spine, trochanter femoral neck, and Ward's BMD differed from before the treatment. A year after treatment, the lumbar spine and trochanter decreased slightly, but were not significantly different. CONCLUSIONS: Our study shows that the administration of GnRH-a plus raloxifene in pre-menopausal women with severe endometriosis, is an effective long-term treatment to prevent bone loss.
